EYPT
pSivida Corp develops tiny, sustained-release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years.
EyePoint, Inc. (EYPT) is rated D+ (1.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Revisions (F). The rating has held at D+ for 3 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-11 | B (3.3) | C+ (2.8) | D- (1.1) | F (0.4) | F (0.0) | D+ (1.5) |
| 2026-11-04 | B (3.3) | C+ (2.8) | D- (1.1) | F (0.4) | F (0.0) | D+ (1.5) |
| 2026-10-28 | B (3.3) | C+ (2.8) | D (1.2) | F (0.4) | F (0.0) | D+ (1.5) |
| 2026-10-21 | B (3.3) | C+ (2.8) | D- (1.1) | F (0.5) | F (0.0) | D+ (1.5) |
| 2026-10-14 | C (2.4) | D (1.4) | D- (1.1) | F (0.5) | F (0.0) | D- (1.1) |